| Title |
Topiramate-induced maculopathy in IgG4-related disease
|
|---|---|
| Published in |
Drug, Healthcare and Patient Safety, June 2016
|
| DOI | 10.2147/dhps.s105962 |
| Pubmed ID | |
| Authors |
Joanna DaCosta, Saad Younis |
| Abstract |
This report describes a case of reversible topiramate-induced maculopathy in a 32-year-old female patient with IgG4-related disease. The patient presented with decreased vision associated with anterior uveitis and cystoid macula edema, which was unresponsive to oral and topical steroids. Following topiramate cessation, both cystoid macula edema and vision improved. The ocular side effects of topiramate and putative pharmacological mechanisms for topiramate-induced maculopathy in the context of IgG4-related disease are discussed. This report highlights that neurologists and ophthalmologists should be aware that patients presenting with topiramate-associated maculopathy should be advised to discontinue topiramate promptly to prevent irreversible loss of vision. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 29% |
| Other | 1 | 7% |
| Student > Doctoral Student | 1 | 7% |
| Student > Bachelor | 1 | 7% |
| Librarian | 1 | 7% |
| Other | 4 | 29% |
| Unknown | 2 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 64% |
| Nursing and Health Professions | 2 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Unknown | 2 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 July 2016.
All research outputs
#20,011,485
of 25,457,858 outputs
Outputs from Drug, Healthcare and Patient Safety
#128
of 160 outputs
Outputs of similar age
#254,726
of 353,828 outputs
Outputs of similar age from Drug, Healthcare and Patient Safety
#2
of 2 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 160 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,828 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.